Indeed, several ongoing clinical trials utilize CRISPR/Cas9 to delete PDCD1, including one that has been deemed safe and feasible for late-stage non-small cell lung cancer (NSCLC) patients (ClinicalTrials.gov NCT02793856; Lu et al., 2020; Wang et al., 2020). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.